Complications of orthopedic treatment in patients diagnosed with X-linked hypophosphatemic rickets
Author:
Paludan Carl Gustaf1, Thomsen Kristoffer Koed Vittrup1, Rahbek Ole1, Kold Søren1
Affiliation:
1. Department of Orthopaedics, Interdisciplinary Orthopedics, Aalborg University Hospital , Aalborg , Nordjylland , Denmark
Abstract
Abstract
Objectives
XLHR in children with a Rickets Severity Score ≥2 can now be treated with the new antibody drug, Burosumab, which prevents bone deformities and increases gait endurance. This study illustrates the extent of complications in the traditional orthopedic treatment of XLHR. The impact of surgery and severity of complications in this patient population has not been systematically assessed before.
Methods
The search strategy resulted in 215 studies and data were collected from 19 eligible studies and complications were categorized. Four medical charts of patients with XLHR at Aalborg University Hospital were assessed.
Results
One complication occurred on average per surgical procedure for XLHR in the published literature. The 168 reported complications were categorized as follows: Type I (n=79): Complications with minimal intervention required and treatment goal still achieved, Type II (n=41): Complications with substantial change in treatment plan and treatment goal still achieved, Type IIIA (n=23): Complications with failure to achieve treatment goal and no new pathology or permanent sequelae, Type IIIB (n=25): Complications with failure to achieve treatment goal and/or new pathology or permanent sequelae.
Conclusions
In average, one complication occurred per surgery and the severity of complications were substantial. The treatment goal was not achieved in 28% of surgeries whereof half of them resulted in permanent sequalae or new pathology. Our findings support the use of Burosumab for treatment of the skeletal changes in XLHR as the reported side-effects in Burosumab treatment appear negligible compared to the impact of surgeries and related complications (Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward LM, Nilsson O, et al. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet 2019;393:2416–27). However, orthopedic surgery might still be needed for correcting deformities restricting activities of daily living in XLHR patients.
Publisher
Walter de Gruyter GmbH
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Pediatrics, Perinatology and Child Health
Reference25 articles.
1. Beck-Nielsen, SS, Brusgaard, K, Rasmussen, LM, Brixen, K, Brock-Jacobsen, B, Poulsen, MR, et al.. Phenotype presentation of hypophosphatemic rickets in adults. Calcif Tissue Int 2010;87:108–19. https://doi.org/10.1007/s00223-010-9373-0. 2. Horn, A, Wright, J, Bockenhauer, D, Van’t Hoff, W, Eastwood, DM. The orthopaedic management of lower limb deformity in hypophosphataemic rickets. J Child Orthop 2017;11:298–305. https://doi.org/10.1302/1863-2548.11.170003. 3. Lyseng-Williamson, K. Burosumab in X-linked hypophosphatemia: a profile of its use in the USA. Drugs Ther Perspect 2018;34:497–506. https://doi.org/10.1007/s40267-018-0560-9. 4. Carpenter, TO, Whyte, MP, Imel, EA, Boot, A, Högler, W, Linglart, A, et al.. Burosumab therapy in children with X-linked hypophosphatemia. N Engl J Med 2018;378:1987–98. https://doi.org/10.1056/nejmoa1714641. 5. Portale, A, Imel, EA, Whyte, MP, Boot, A, Högler, W, Linglart, A, et al.. Burosumab for X-linked hypophosphatemia (XLH): results from two pediatric phase 2 tri-als [abstract no. 525]. Endocr Pract 2018;24(1 Suppl):119–20. https://doi.org/10.1016/s1530-891x(20)47202-7.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|